top of page
    • Nov 12, 2019
    • 1 min read

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans




bottom of page